Haemoglobin fluctuations in patients on haemodialysis treated with ESAs: clinical observations from two centres

References

• Locatelli F, Aljama P, Bárány P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1-47
   PubMedGoogle Scholar
• Pollock C, McMahon L. The CARI guidelines. Biochemical and haematological targets guidelines. Haemoglobin. Nephrology (Carlton) 2005;10(Suppl 4):S108-15
   PubMedGoogle Scholar
• KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2007;50:471-530
   Google Scholar
• Centers for Medicare & Medicaid Services 2004 Annual Report, End Stage Renal Disease Clinical Performance Measures Project. Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards & Quality, Baltimore, Maryland, December 2004
   Google Scholar
• Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:94-111
   PubMed Web of Science ®Google Scholar
• U.S. Renal Data System, USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2005
   Google Scholar
• Li S, Collins AJ Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 2004;65:626-33
   PubMed Web of Science ®Google Scholar
• Lacson E Jr, Ofsthun N, Lazarus JM Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003;41:111-24
   PubMed Web of Science ®Google Scholar
• Ebben JP, Gilbertson DT, Foley RN, et al. Hemoglobin level variability: associated with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205-10
   PubMed Web of Science ®Google Scholar
• Moeller S, Gioberge S, Brown G. ESRD patients in 2001: global overview of patients, treatment modalities and development trends. Nephrol Dial Transplant 2002;17:2071-6
   PubMed Web of Science ®Google Scholar
• 27th ANZDATA Registry 2004 Report. Available at: http://www.anzdata.org.au/. [Accessed January 2008]
   Google Scholar
• Hsu CY, Vittinghoff E, Lin F, et al. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004;141:95-101
   PubMed Web of Science ®Google Scholar
• Roderick P, Davies R, Jones C, et al. Simulation model of renal replacement therapy: predicting future demand in England. Nephrol Dial Transplant 2004;19:692-701
   PubMed Web of Science ®Google Scholar
• Ofsthun NJ, LaBrecque J, Keen M, et al. The association of mortality and hospitalization with hemoglobin (Hb) and missed dialysis treatments in stage 5 chronic kidney disease (CKD) patients with and without cardiac comorbidities. Nephrol Dial Transplant 2005;20(Suppl 5):v268
   Google Scholar
• Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90
   PubMed Web of Science ®Google Scholar
• Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-8
   PubMed Web of Science ®Google Scholar
• Fishbane S, Berns JS Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005;68:1337-43
   PubMed Web of Science ®Google Scholar
• Berns JS, Elzein H, Lynn RI, et al. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003;64:1514-21
   PubMed Web of Science ®Google Scholar
• Collins AJ, Brenner RM, Ofman JJ, et al. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005;46:481-8
   PubMed Web of Science ®Google Scholar
• Israni RK, Yang W, Joffe M, et al. A novel method of measuring haemoglobin variability in hemodialysis patients. J Am Soc Nephrol 2006;17:582A
   Google Scholar
• Gunnel J, Yeun JY, Depner TA, et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999;33:63-72
   PubMed Web of Science ®Google Scholar
• Fishbane S. Recombinant human erythropoietin: has treatment reached its full potential?. Semin Dial 2006;19:1-4
   PubMed Web of Science ®Google Scholar
• Macdougall IC Optimizing the use of erythropoietic agents – pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002;17:66-70
   PubMed Web of Science ®Google Scholar
• Egrie JC, Browne JK Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001;16:3-13
   PubMed Web of Science ®Google Scholar
• Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991;50:702-12
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-5
   PubMed Web of Science ®Google Scholar
• Allon M, Kleinman K, Walczyck M, et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther 2002;72:546-55
   PubMed Web of Science ®Google Scholar
• Jamal NM, Krzyzanski W, Cheung W, et al. Evaluation of epoetin alpha (rHuEPO) and darbepoetin alpha (DARB) on human burst-colony formation BFU-E) in culture. J Int Med Res 2006;34:42-51
   PubMed Web of Science ®Google Scholar
• Walker R, Pussell BA Fluctuations in haemoglobin levels in haemodialysis patients receiving intravenous epoetin alfa or intravenous darbepoetin alfa. Nephrology 2007;12:448-51
   PubMed Web of Science ®Google Scholar
• West RM, Harris K, Gilthorpe MS, et al. Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia. J Am Soc Nephrol 2007;18:2371-6
   PubMed Web of Science ®Google Scholar
• Levin NW, Fishbane S, Valdés Cañedo F, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007;370:1415-21
   PubMed Web of Science ®Google Scholar
• Sulowicz W, Locatelli F, Ryckelynck J-P, et al. on behalf of the PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007;2:637-46
   PubMed Web of Science ®Google Scholar